Psychedelics biotech firm Clearmind Medicine Inc. (OTC: CMNDF) (NASDAQ: CMND) has announced the pricing of its underwritten public offering of 1,153,847 common shares at a public price of $6.50 per share, for aggregate gross proceeds of $7.5 million, to close on or about November 17, 2022

All shares within the offering cannot be sold, transferred, hypothecated or traded on or through facilities of Canadian securities exchange, in Canada, nor for the benefit of a Canadian resident until March …

Full story available on Benzinga.com